Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
McDonald's China Faces Backlash for Food Hygiene Violations 
How supermarkets are changing their branding to make you think they’re cheaper 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
Green industry yes, conservation no: a budget for people, not for nature 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
SEATTLE, Sept. 29, 2017 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured presenter at The MicroCap Conference on Thursday October 5, 2017 at 12:30 PM Eastern Time. The conference is being held at the Essex House in New York City. Mr. Guse will also be available for one-on-one meetings with the investment community.
About Atossa Genetics
Atossa Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
866 893-4927
[email protected]
Investor Relations Contact
Scott Gordon
CorProminence LLC
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516.222.2560
[email protected]
